Remove 2025 Remove Adverse Reactions Remove Labelling
article thumbnail

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

LifeProNow

January 30, 2025: “The U.S. The most common adverse reactions in study participants who received Journavx were itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.

article thumbnail

9 Sneaky Thyroid Toxins Hiding in Your Home

The Thyroid Pharmacist

to fluoride in my tap water, to hidden mold in my home, to my shampoo and deodorant (have you ever read those labels?!), 16] Even more concerning, of the 133 different VOCs found across all tested products, only one, ethanol, was actually listed on any label! From indoor pollutants like formaldehyde (yes, really!),

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Pharmacy Times

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. The CRL was received after OLC’s initial Prescription Drug User Fee Act date of June 28, 2025, and cited for deficiencies that are unrelated to OLC itself. June 30, 2025. News release.

article thumbnail

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Pharmacy Times

3 The safety profile was favorable with the most common adverse effect (AE) being increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

ID Stewardship

Authored By: Aneeka Chavda, MRPharmS, MSc, MCMI, PgDipClinPharm Posted 19 June 2025 Mycobacterium tuberculosis (TB ) is one of the leading causes of death globally. Finally, the use of fluoroquinolones are discussed, especially for drug-resistant or intolerant patients, noting their potential in CNS TB and as part of shorter-course therapies.

article thumbnail

FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment

Express Pharma

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for August 31, 2025. The BLA submission is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modelling of observed data. Eisai holds final decision-making authority.